Lung Cancer Diagnostics Market: Overview The lung cancer diagnostics market expects to observe considerable growth during the forecast period of 2019-2028. The growth is largely dependent on the rising rate of tobacco consumption, especially smoking. According to the World Health Organization (WHO), tobacco consumption kills at least 6 million people every year. Tobacco, being the major cause of lung cancer may lead the lung cancer diagnostics market toward growth. Other factors such as alcohol use, infection-carrying agents such as human papilloma virus (HPV), pollution, and occupational carcinogens also attribute to the increase in lung cancer patients. This upcoming report on the lung cancer diagnostics market provides an in-depth analysis of the current market situation. The report covers components like competitive landscape, key players, regional analysis, and ongoing trends. The report also offers thorough research of the COVID-19 pandemic impact on lung cancer diagnostics market. The segmental study enables an individual to thoroughly understand the deep packet inspection market. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=74159 Lung Cancer Diagnostics Market: Competitive Analysis and Key Developments The manufacturers in the lung cancer diagnostics market consistently focus on research and development activities. Being highly competitive, the lung cancer diagnostics market is characterized by frequent technological innovations to improve the cancer diagnosis speed. Furthermore, to strengthen the footprint in the sector, collaborations, partnerships, joint ventures, mergers, and acquisitions are a common norm in the lung cancer diagnostics market. Key players involved in the lung cancer diagnostics market are bioMerieux, QIAGEN N.V., Roche Diagnostics, and Illumina Inc.
Roche Diagnostics recently launched a non-small-cell lung carcinoma diagnostic kit to enhance the quality of lung cancer screening Recently, new research was conducted on the development of an electric nose for lung cancer diagnosis. It identifies chemicals in a patient’s body through breath and predicts whether s/he will respond to immunotherapy or not A new technology developed by scientists at MIT’s Koch Institute enables lung cancer detection through a urine test
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=74159 Lung Cancer Diagnostics Market: Key Trends The COVID-19 outbreak has put many lives at risk. Over 20 million people are infected by the novel coronavirus. Early detection is key to avoid the spread of SARS-CoV-2. A recent article in Annals of Oncology recommended testing for patients having lung cancer, as they are more at risk of infected with COVID-19. Therefore, this factor will boost the growth of the lung cancer diagnostics market as more people will test for early detection.